drugset / Trial / NCT00019487

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019487

Treatment

Summary

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to previous therapy.

Timeline

Start
1998-11
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Intravenous
Subject gp209-2M Peptide Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified

Indications